Abstract:
Finasteride, a specific and competitive inhibitor of 5α-reductase enzyme Type 2, inhibits the conversion of testosterone
to dihydrotestosterone (DHT). In adults, DHT acts as primary androgen in prostate and hair follicles. The only
FDA-approved dermatological indication of finasteride is androgenetic alopecia. But, apprehension regarding sexual
dysfunction associated with finasteride deters dermatologists from prescribing the drug and patients from taking the
drug for androgenetic alopecia.
